Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
31st December 2020 | David G Foster | 11,052 | Open or private sale | $6.38 | $70,511.76 |
31st December 2020 | Anna Berkenblit | 2,203 | Grant/award etc. | $4.04 | $8,900.12 |
31st December 2020 | David G Foster | 362 | Grant/award etc. | $4.04 | $1,462.48 |
31st December 2020 | David G Foster | 27,240 | Exercise of derivative | $0.00 | |
31st December 2020 | Theresa Wingrove | 2,659 | Grant/award etc. | $4.04 | $10,742.36 |
1st July 2020 | David G Foster | 342 | Grant/award etc. | $3.91 | $1,337.22 |
30th June 2020 | Anna Berkenblit | 3,047 | Grant/award etc. | $3.91 | $11,913.77 |
30th June 2020 | Mark J Enyedy | 5,241 | Grant/award etc. | $3.91 | $20,492.31 |
30th June 2020 | Thomas Ryll | 5,241 | Grant/award etc. | $3.91 | $20,492.31 |
30th June 2020 | Theresa Wingrove | 2,593 | Grant/award etc. | $3.91 | $10,138.63 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
ImmunoGen, Inc. was founded in March 1981 and is headquartered in Waltham, MA. Its product candidates include Mirvetuximab soravtansine, Coltuximbe ravtansin, IMGN7779 and IMGN632.
24th February 2021
9th December 2020